Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients

Optimal care for breast cancer patients undergoing aromatase inhibitor (AI) treatment is ensured when estradiol (E(2)) levels are adequately suppressed. To assess treatment efficacy accurately, it is important to measure the serum E(2) levels using a well validated assay method with high sensitivity and specificity. This translates into the urgent need to evaluate various E(2) immunoassay kits, which are frequently used in hospital settings to measure E(2) serum levels in patients undergoing AI treatment, so clinicians obtain accurate and reliable measurements allowing appropriate clinical decision making. Our objective was to evaluate the performance of different commercially available and commonly used E(2) immunoassay kits regarding measurement of E(2) levels in the serum of postmenopausal breast cancer patients treated with AIs, in comparison to a highly accurate and reliable mass spectrometry assay. Clinical and demographic data were obtained from 77 postmenopausal breast cancer patients who were treated with an AI. Serum E(2) levels were measured by 6 immunoassay methods and by liquid chromatography-tandem mass spectrometry (LC-MS/MS), which served as the standard for comparison. Analysis of E(2) by LC-MS/MS showed that 70% of the samples had levels that were <5 pg/ml. Three of the assays carried out with commercial E(2) immunoassay kits had poor sensitivities and were not able to detect E(2) levels <10 or <20 pg/ml. Although two of the E(2) assays using commercial kits demonstrated a better sensitivity (5 pg/ml), the measured E(2) values were substantially higher than those obtained by LC-MS/MS. The assay with the sixth commercial E2 kit grossly underestimated the true E(2) values. E(2) assays carried out with commercial E(2) immunoassay kits lack the accuracy to measure the very low serum E(2) levels found in patients being treated with AIs. Serum samples from such patients should be sent to laboratories that use a mass spectrometry assay. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2193-1801-2-5) contains supplementary material, which is available to authorized users.